Trial Profile
A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2012
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jul 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jul 2010 Planned end date changed from 1 Jan 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.